Shares of Avinger, Inc. (NASDAQ:AVGR) Advance Following Approval for In-Stent Restenosis Treatment

Shares of Avinger, Inc. (NASDAQ:AVGR) Advance Following Approval for In-Stent Restenosis Treatment

Leading developer of innovative treatments for Peripheral Artery Disease, Avinger, Inc. (NASDAQ:AVGR), announces that it has received CE Marking approval for treating in-stent restenosis with their patented Pantheris Lumivascular atherectomy system as the share price advances. REDWOOD CITY, Calif., Sept. 26, 2017 (GLOBE NEWSWIRE) — Avinger, Inc. (AVGR), a leading developer of innovative treatments for Peripheral Artery Disease (PAD), today announced Conformité Européenne (CE) Marking approval for treating in-stent restenosis […]

Read More ˃